Aktie A2PYCU INTERPACE BIOSCIENCES, INC.
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren
Inaktiver Wert

Andere Sprachen Interpace Biosciences, Inc. Other OTC

Aktien

A2PYCU

US46062X3035

IDXG

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
Interpace Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
Interpace Biosciences Announces First Quarter 2024 Financial and Business Results
Earnings Flash (IDXG) INTERPACE BIOSCIENCES Reports Q4 Revenue $10.3M
Interpace Biosciences Announces Preliminary Full-year and Fourth Quarter 2023 Financial and Business Results
Interpace Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Interpace Biosciences, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
Robert Gorman Provides Notice to Interpace Biosciences, Inc. of His Resignation as A Director and as Chairman of the Board, Including as A Member of the Board?s Regulatory Compliance Committee
Interpace Biosciences, Inc. Announces Resignation of Edward Chan as Class II Director
Interpace Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Interpace Biosciences Announces Record Third Quarter 2023 Financial and Business Results
Interpace Biosciences, Inc. Enters Amendment to Loan Security Agreement with Broadoak Fund V, L.P
Interpace Biosciences Announces Record Second Quarter 2023 Financial and Business Results
Interpace Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
Interpace Biosciences, Inc. Appoints Christopher Mccarthy as Chief Financial Officer
Interpace Biosciences Releases Preliminary Record Second Quarter 2023 Business Results; Updates Status of PancraGEN® Reimbursement
Interpace Expects to Stop Offering PancraGEN® Test Due to CMS Decision to End Reimbursement as of July 17, 2023
Interpace Biosciences, Inc. Expects to Stop Offering Pancragen Test Due to CMS Decision to End Reimbursement as of July 17, 2023
Interpace Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
Earnings Flash (IDXG) INTERPACE BIOSCIENCES Reports Q1 Revenue $9.8M
Interpace Biosciences Announces Record First Quarter 2023 Financial and Business Results
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. A2PYCU Aktie
  4. A2PYCU Aktie
  5. Nachrichten Interpace Biosciences, Inc.
  6. Andere Sprachen